The latest announcement is out from Aurinia Pharmaceuticals ( (AUPH) ).
Aurinia Pharmaceuticals Inc. announced a board restructuring on September 12, 2024, aimed at enhancing alignment with shareholder interests. The restructure includes the appointment of Kevin Tang as a new director and the acceptance of conditional resignations from three directors who lacked majority support at the recent Annual General Meeting. Peter Greenleaf, despite his conditional resignation due to less than majority support, remains a director under special circumstances deemed beneficial for the company’s focus on commercial execution and pipeline advancement. The board now consists of seven members, reflecting the company’s commitment to strategic governance and shareholder value.
For a thorough assessment of AUPH stock, go to TipRanks’ Stock Analysis page.
